Physician profile
Ethan E Larson
NPI 1871741124
$7,898.05
in general payments reported to CMS, 2019-2025
14 companies · $563 in 2025
The $563 reported for 2025 was more than what a typical Plastic Surgery provider received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,173 · 2020: $249 · 2021: $919 · 2022: $350 · 2023: $18.12 · 2024: $626 · 2025: $563.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $941 · Travel and Lodging: $266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $940.51 |
| Travel and Lodging | $266.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apyx Medical Corporation | $4,661.46 | 2019-2020 | |
| Sientra, INC. | $702.30 | 2019-2022 | |
| Motiva USA, LLC | $505.77 | 2025 | |
| Stryker Corporation | $368.82 | 2019-2021 | |
| Abbvie INC. | $301.55 | 2024 | |
| Integra Lifesciences Corporation | $290.80 | 2019 | |
| Allergan, INC. | $236.59 | 2019-2022 | |
| Revance Therapeutics, INC. | $202.14 | 2024-2025 | Daxxify |
| Mentor Worldwide LLC | $179.25 | 2024 | Mentor Memorygel Resterilizable Gel Sizer |
| Galderma Laboratories, L.P. | $114.96 | 2019-2022 | |
| Bard Peripheral Vascular, INC. | $106.11 | 2021 | |
| Medical Device Business Services, INC. | $100.04 | 2019 | |
| Tela Bio, INC. | $84.85 | 2021-2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Derma Sciences, INC. | $43.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ethan Larson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.